Cointime update: China’s National Healthcare Security Administration said on Nov. 14 that relma-cel, a CAR-T therapy from JW Therapeutics, has been added to the national medical insurance list. Before inclusion, relma-cel was priced at 1.29 million yuan per infusion. Ma Jun, director of the Harbin Institute of Hematology and Oncology, who took part in the drug’s review and clinical-use consensus, said the price has fallen below 300,000 yuan per infusion following the listing.
China Adds WuXi Biologics’ CAR-T Therapy Relma-cel to National Insurance
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
1h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
1h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips
2h ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
2h ago
Goldman Sachs Forecasts Gold May Return to $5,600 by Late 2028
3h ago
Dollar Holds Near 19-Month High on Fed Rate Hike Expectations